Early disarticulation of a bioresorbable vascular scaffold: an underreported consequence of repeat imaging
Compliance with ethical standards
Conflict of interest
Dr. West has acted as a consultant for Abbott Vascular. Dr. Hoole has acted as a consultant for St. Jude Medical and Abbott Vascular. All other authors have no conflicts of interest to declare.
Supplementary material 1 (MPG 140492 kb)
- 1.Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122(22):2301–12.CrossRefPubMedGoogle Scholar
© Japanese Association of Cardiovascular Intervention and Therapeutics 2017